Johnson & Johnson Coronavirus vaccine illustration
Dado Ruvic | Reuters
Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that beat Wall Street’s expectations.
Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:
- Adjusted EPS: $1.86 per share versus $1.82 expected.
- Revenue: $22.48 billion versus $21.67 billion expected.
“I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs,” J&J CEO Alex Gorsky said in a press release. “We continue to progress our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon.”
This is a developing story. Please check back for updates.
This article was originally published by Cnbc.com. Read the original article here.